Bionics Institute
David Szmulewicz is a Principal Research Fellow at the Bionics Institute and has held an Associate Professor position at the University of Melbourne since January 2011, where responsibilities include being a Senior Lecturer and Examiner in the Faculty of Medicine, Dentistry and Health Sciences and establishing the St Vincent’s Hospital Clinical School balance disorders training program. David Szmulewicz also serves as a Neurologist at the MACHADO JOSEPH S DISEASE FOUNDATION INC and Monash Health, as well as in various positions at Alfred Health and Epworth HealthCare, contributing to balance disorder clinics. David Szmulewicz's editorial involvement includes serving on the editorial board of BioMed Central's Cerebellum and Ataxias and participation in the National Health and Medical Research Council as an Early Career Research Fellow. Educational credentials include a Ph.D. from the University of Melbourne and multiple degrees in Medicine and Surgery from Monash University.
This person is not in the org chart
Bionics Institute
The Bionics Institute is an internationally recognised, independent medical research institute that solves medical challenges with technology. We lead the world in the research and development of innovative medical devices and therapies to improve human health. Our multidisciplinary team is comprised of world-class scientists, engineers and researchers, and our laboratories are located in St Vincent’s Hospital Melbourne, close to our clinical collaborators. Together we transform the lives of people with a range of conditions, including Alzheimer’s disease, hearing impairment, vision loss, Crohnʼs disease, Parkinsonʼs disease, stroke, arthritis, incontinence and diabetes. The Bionics Institute has an impressive track record of translating medical device concepts into clinical reality dating back to 1986 when it was founded by Professor Graeme Clark, leader of the team that created Australiaʼs cochlear implant. Since then, Bionics Institute researchers have developed: • Australiaʼs first-generation bionic eye prototype implanted in clinical trials in 2018. - The epilepsy seizure monitoring device Minder™, commercialised through Epi-Minder Pty Ltd. - An adaptive deep brain stimulation system for Parkinsonʼs disease, commercialised through Deep Brain Stimulation Technologies Pty Ltd. - An innovative vagus nerve stimulation device to treat inflammatory bowel disease, which is moving into clinical trials and also being adapted to treat rheumatoid arthritis and diabetes. - Novel drug delivery methods for hearing loss; new diagnostic tools for improved diagnosis of infant hearing. Growth into new areas will build on our expertise in medical device development and a recent expansion of our world-class facilities to include the end-to-end medical device prototype manufacturing facility, Neo-Bionica.